We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

News · June 01, 2020

ASCO 2020: Adjuvant Osimertinib Therapy Dramatically Improves Outcomes in Non–Small Cell Lung Cancer

Disease-free survival was so much greater among patients who took the drug for up to 3 years that the study was unblinded early

PracticeUpdate Editorial Team

 

Further Reading